Complex osteochondral lesions of the talus treated with a novel bi-phasic aragonite-based implantDrobnič, Matej (Avtor) Kolar, Matic (Avtor) Verdonk, Peter (Avtor) Vannini, Francesca (Avtor) Robinson, Dror (Avtor) Altschuler, Nir (Avtor) Shabshin, Nogah (Avtor) Kon, Elizaveta (Avtor) Agili-C™anklearagonitebiodegradable implantsbi-phasic implantscartilageosteochondral lesionsscaffoldtalusTo present initial results of a novel, bi-phasic, porous, biodegrade, and cell-free aragonite-based scaffold for treating complex osteochondral lesions of the talus (OLT). Four subjects (2 males and 2 females; 34-61 years old) were operated on their ankles due to chronic and deep OLT-Hepple grades 4 or 5 (1.8-2.2 cm$^2$). Three subjects had OLT on the medial central trochlea, and 1 had a combined medial and lateral lesions. OLT were exposed through medial malleolus osteotomy, with an additional lateral arthrotomy in the combined lesions. Bi-phasic porous osteochondral scaffolds (single implant or 2 implants) were implanted in a press-fit manner using a designated surgical toolset. Treatment outcome was followed clinically (Foot and Ankle Outcome Score, EQ-5D 3L, Tegner activity scale) and by medical imaging (radiographs, magnetic resonance imaging) from 18 to 32 months. All Foot and Ankle Outcome Score values increased from preoperative to final follow-up values (Symptoms 62 to 71, Pain 53 to 84, ADL 60 to 89, Sport 19 to 65, and QoL 18 to 47). EQ-5D 3L increased from 0.59 to 0.76, and Tegner activity values increased from 1.5 to 3. Kellgren-Lawrence ankle radiographic scores remained stable (2 to 2). Postoperative MR evaluation demonstrated cartilage defect fill of 75% to 100% respect to the native cartilage in 3 subjects (4 OLTs), while 1 lesion was filled 25% to 50%. No graft related serious adverse events or graft failures were reported. The use of a bi-phasic osteochondral biodegradable aragonite-based scaffold in the treatment of complex OLT during the reported period presented positive and promising clinical and radiologic outcome, without serious adverse events or graft failures.20212022-07-20 12:48:15Članek v reviji138433UDK: 617.3ISSN pri članku: 1067-2516DOI: 10.1053/j.jfas.2020.06.028COBISS_ID: 108232451sl